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ABSTRACT

Background
Although people who use drugs (PWUD) are a key population recommended to
receive pre-exposure prophylaxis (PrEP) to prevent HIV, few data are available to guide
PrEP delivery in this underserved group. We therefore examined the willingness to
initiate PrEP, the anticipation of HIV risk reduction while on PrEP, and the acceptability
of PrEP based on a number of known PrEP attributes among high-risk PWUD.

Methods
In a cross-sectional study of 400 HIV-negative, opioid dependent individuals
enrolled in a methadone program and reporting recent risk behaviors, we examined
independent correlates of being willing to initiate PrEP. Participants also ranked the
eight hypothetical PrEP program scenarios with varied combinations of six attributes
related to PrEP (cost, dosing, efficacy, side-effects, treatment setting, and frequency of
HIV testing).

Results
While only 72 (18%) were aware of PrEP, after being given a description of it,
251 (62.7%) were willing to initiate PrEP. Willingness to initiate PrEP was associated
with having neurocognitive impairment (aOR=3.184, p=0.004) and higher perceived HIV
risk (aOR=8.044, p<0.001). Among those willing to initiate PrEP, only 12.5% and
28.2%, respectively, indicated that they would always use condoms and not share
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injection equipment while on PrEP. PrEP acceptability ranged from 30.6% to 86.3% with
a mean acceptability of 56.2% across the eight hypothetical PrEP program scenarios.
The PrEP program scenario with the highest acceptability had the following attribute
levels: insurance covered, daily dosing, 95% effective, no side-effects, treatment at HIV
clinic, and HIV testing needed every six months.

Conclusions
Our findings showed high acceptability of PrEP in response to different PrEP
program scenarios with different attribute profiles. While willingness to initiate PrEP was
high and correlated with being at elevated risk for HIV and having NCI, anticipated
higher risk behaviors in this group even while on PrEP suggests that the next
generation of HIV prevention approaches may need to combine biomedical and
behavioral components to improve adherence to PrEP and to sustain HIV risk reduction
over time.

ix

INTRODUCTION

Background
HIV (Human Immunodeficiency Virus) continues to be a major global public
health issue. Since the start of the epidemic, more than 70 million people have become
infected with HIV globally and 35 million have died of AIDS-related illnesses. In 2016
alone, approximately 36.7 million people were living with HIV (PLWH), including 1.8
million children, with a global HIV prevalence of 0.8% among adults aged 15-49 years.
The same year, there were roughly 1.8 million new HIV infections – a decline from 2.1
million new infections in 2015, and about 1 million deaths from HIV-related illnesses
were reported in the same year (UNAIDS, 2017). The burden of the epidemic continues
to vary considerably between countries and regions, with the vast majority of PLWH
located in low- and middle- income countries.
HIV remains a persistent problem for the United States as well. The Centers for
Disease Control and Prevention (CDC) estimated that a 1.1 million people in the United
States were living with HIV at the end of 2014. Nearly one in seven of those are
unaware of their HIV sero-status. In 2014, there were an estimated 37,600 new HIV
infections, which represents a decline of 10% from 2010 (CDC, 2016b). The size of the
epidemic is relatively small compared to the country’s population, but is heavily
concentrated among several key affected populations. Most new HIV infections occur
among men who have sex with men (MSM), with African American/black men who have
sex with men most affected. African American/black heterosexual women are also
disproportionately affected (CDC, 2016b).
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According to the recent CDC estimates, of the 1.1 million PLWH in the United
States in 2014, an estimated 85% were diagnosed. This means that 15%
(approximately 1 in 6 PLWH) were unaware of their infection and therefore not
considering the care and treatment they need to stay healthy. Of those PLWH, 62%
received HIV-related care, 48%
were retained in care, and 49%
had achieved viral suppression. In
other words, approximately 3 out
of 5 PLWH had the virus under
control (CDC, 2016c). The CDC
further estimated that 9 out of 10
HIV infections were transmitted by
people who are not diagnosed or
not in care. Reducing the number
of undiagnosed HIV infections and

Figure 1: HIV continuum of care, U.S., 2014 (CDC, 2016c)

getting more people into care
present the greatest opportunities to improve viral suppression in America. This
underscores the importance of continued and intensified efforts to reach more people
with testing and to make sure that those with the HIV receive prompt, ongoing care and
treatment to help them live longer, healthier lives and prevent the spread of HIV to
others.
From the outset of the HIV epidemic, the use of substance, including alcohol use,
injection drug use (IDU), and non-IDU, has been closely associated for its potential

2

influence on HIV disease progression (Degenhardt et al., 2013). Despite the recent
decline in the proportion of HIV infections attributed to people who use drugs (PWUD)
(CDC, 2016b), they still remain a priority population because of the potential for an
increase in HIV transmission as a result of preventable drug-related (e.g., needle
sharing) and sex-related (e.g., inconsistent condom use) risk behaviors (Alipour,
Haghdoost, Sajadi, & Zolala, 2013; Marshall et al., 2014; Nadol et al., 2016; Strathdee
et al., 2010; Volkow & Montaner, 2011). Failing to effectively intervene with PWUD has
resulted in poor individual outcomes, and also threatens public health by increasing the
likelihood of HIV transmission via PWUD. These high-risk individuals – and the
communities in which they live – would greatly benefit from improving and expanding
existing EBIs, and introducing new approaches to HIV prevention.
HIV oral pre-exposure prophylaxis (PrEP), which involves routine selfadministration of antiretroviral medication, TruvadaTM (Tenofovir/emtricitabine),
represents a significant innovation in our public health response to reduce the HIV
epidemic. Large-scale clinical trials have proven daily PrEP to be safe, well-tolerated,
and efficacious for reducing HIV infection among those who are at substantial risk of
acquiring HIV infection, such as men who have sex with men (MSM), people who inject
drugs (PWID), sex workers, and transgender people (Baeten et al., 2012; Choopanya
et al., 2013; Grant et al., 2010; Thigpen et al., 2012; Van Damme et al., 2012). Based
on this evidence, the World Health Organization (WHO) and the US Centers for Disease
Control and Prevention (CDC) have recommended PrEP for individuals at substantial
risk for HIV infection (CDC, 2014; WHO, 2015), and the US National HIV/AIDS Strategy
through 2020 priorities have expanded access to comprehensive PrEP services among
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those who are interested and may benefit (The White House Office of National AIDS
Policy, 2015).
Despite the unequivocal evidence and widespread PrEP availability in the US
and its coverage by almost all insurance, its uptake among the most-at-risk populations,
has been strikingly low (Kirby & Thornber-Dunwell, 2014), and non-existent among
PWUD. The overall success of the PrEP strategy, which hinges heavily on PrEP uptake,
involves a high level of user awareness, willingness to use it, and compliance (Peng et
al., 2012). In recent years, there has been growth in studies examining attitudes,
awareness, and willingness to use PrEP, especially among MSM, with limited research
among high-risk PWUD (Ferrer et al., 2016; Goedel, Halkitis, Greene, & Duncan, 2016;
Gredig, Uggowitzer, Hassler, Weber, & Nideröst, 2016; Hoagland et al., 2016; Holt et
al., 2012; Kuo et al., 2016; Peng et al., 2012; Stein, Thurmond, & Bailey, 2014; Young,
Li, & McDaid, 2013). Whether or not PWUD enrolled in substance abuse treatment
would be willing to initiate PrEP, however, has not be explored. Furthermore, no prior
studies have assessed individuals’ anticipated likelihood of engaging in safer drug use
(i.e., not sharing of needles/works) and safer sex (i.e., consistent condom use) while on
PrEP among PWUD within a drug treatment setting (e.g., methadone maintenance
program: MMP) where high risk individuals are concentrated.
PrEP programs developed based on stakeholders’ preferences may improve
successful identification, engagement, and adherence of individuals at substantial risk
for HIV infection in PrEP care, as highlighted in the PrEP cascade. In this context, few
studies have assessed information about individuals’ attitudes and preferences of
various attributes (e.g., cost, side-effects, dose, dispensing venue, etc.) of PrEP
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programs. Those studies were, however, focused mostly among MSM (Eisingerich et
al., 2012; Galea et al., 2011a; Wheelock et al., 2013), and no such studies have been
conducted among PWUD within a drug treatment setting (e.g., methadone maintenance
program: MMP) where high risk individuals are concentrated. As demonstration projects
are beginning to develop, there is an urgent need to understand how high-risk PWUD
value various aspects of PrEP programs.
A variety of behavioral, clinical, service delivery, socio-cultural, and other
structural challenges represent a significant challenge to PrEP implementation among
this underserved population. Prior studies have primarily focused on other risk
populations, including MSM and transgender individuals, and no studies have been
conducted among PWUD within a MMP to assess patients’ willingness to use PrEP nor
the influence of various attributes on PrEP program acceptability. A novel aspect of this
thesis is that the results from this study will be the first to offer valuable insights that can
help care providers implement PrEP more effectively among PWUD by focusing our
efforts on the most critical aspects of PrEP treatment. Importantly, this study will provide
preliminary evidence to inform the initiation of PrEP services and integration of
additional strategies (e.g., behavioral interventions) within MMPs to optimize HIV
prevention efforts.

Research Objectives
The overall objective of this study was to understand individuals’ awareness and
willingness to use PrEP and to investigate preferences about the delivery of the PrEP
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program among high-risk PWUD in treatment. Specifically, three research aims were
proposed to facilitate achieving the overall objective of the study:
•

To assess awareness and willingness to use PrEP among high-risk PWUD in
treatment.

•

To assess demographic and behavioral correlates of willingness to use PrEP
among high-risk PWUD in treatment.

•

To investigate the acceptability of hypothetical PrEP programs and the impact of
various PrEP attributes on PrEP program acceptability among high-risk PWUD in
treatment.

6

LITERATURE REVIEW

Available HIV Prevention Strategies
Over the last three decades, research has led to a growing number of efficacious
and cost-effective strategies to reduce the risk of HIV infection. Many of these
approaches can be particularly effective when tailored to address the social, community,
financial, and structural factors that place specific groups at risk. In the United States,
proven strategies (CDC, 2016a) include:
HIV testing and linkage to care: Testing is a critical component of prevention
efforts because when people learn they are infected, research shows that they take
steps to protect their own health and prevent HIV transmission to others. Linkage to
care helps ensure PLWH receive life-saving medical care and treatment, and helps
reduce their risk of transmitting HIV (Christopoulos et al., 2011).
Antiretroviral therapy (ART): Treating PLWH early in their infection dramatically
reduces the risk of transmitting the virus to others, underscoring the importance of HIV
testing and access to medical care and treatment. Treatment as Prevention (TaP) has
emerged as one of the ways for reducing the risk of transmission from HIV-infected
pregnant women to their infants (Carpenter et al., 2000; WHO, 2012).Access to
condoms and sterile syringes: In order for HIV prevention efforts to work, PWLH, or at
risk for, HIV infection need to have access to effective prevention tools (CDC, 2016a).
Substance abuse treatment: Effective substance abuse treatment that helps
PWUD stop injecting eliminates the risk of HIV transmission through injection drug use
(CDC, 2016a).
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Screening and treatment for other sexually transmitted infections: Many
sexually transmitted infections (STIs) increase an individual’s risk of acquiring and
transmitting HIV, and STI treatment may reduce HIV viral load. Therefore, STI
screening and treatment may reduce risk for HIV transmission (CDC, 2016a).
In addition, pre-exposure prophylaxis, or PrEP, is a new prevention
intervention in which HIV-uninfected people take a daily dose of antiretroviral
medication to lower their chances of acquiring HIV (CDC, 2014; WHO, 2015). The
efficacy of oral PrEP has been shown in recent randomized control trials and is highest
when the drug is used as directed (Baeten et al., 2012; Choopanya et al., 2013; Grant
et al., 2010; Thigpen et al., 2012; Van Damme et al., 2012).

Pre-Exposure Prophylaxis (PrEP)
The recent advent of PrEP has provided unprecedented opportunities in our
public health response to curtail the HIV epidemic. Findings from recent PrEP trials
have demonstrated that daily PrEP dose can significantly reduce the risk of HIV
transmission among those who are at substantial risk of acquiring HIV infection, such as
MSM, people who inject drugs (PWID), sex workers, and transgender people (Baeten
et al., 2012; Choopanya et al., 2013; Grant et al., 2010; Thigpen et al., 2012; Van
Damme et al., 2012). Based on these findings, the CDC released clinical practice
guidelines on the use of PrEP for HIV prevention, identifying high-risk PWUD as one of
the key populations that could benefit from the use of PrEP (CDC, 2014). The
guidelines also indicate that PrEP should be given as an additional prevention choice
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for people who are at substantial risk of HIV infection as part of combination HIV
prevention approaches.

PrEP Guidelines
On the basis of this evidence, the Centers for Disease Control and Prevention
(CDC) issued guidance on the use of PrEP in 2012 and published updated Clinical
Practice Guidelines on 2014 (CDC, 2014). The major area covered by the guidelines
are (Table 1 in appendices):
•

Daily oral PrEP has been shown to be effective in reducing the risk of HIV
acquisition in adults.

•

Current data on the efficacy and safety of PrEP for adolescents are not
sufficient.

•

HIV infection must be excluded by symptom history and HIV testing
immediately before PrEP is prescribed.

•

HIV infection should be assessed at least every 3 months and renal function
at every 6 months after the patients is taking PrEP.

•

Health care provider should provide access, directly or by facilitated referral to
confirmed effective risk-reduction services.

In July 2015, the White House released an updated National HIV/AIDS Strategy
for the United States, which highlights PrEP as a main tool in preventing HIV (The White
House, 2015). In 2012, World Health Organization (WHO) endorsed the use of PrEP to
MSM, sero-discordant couples, and transgender people (World Health Organization,
9

2012). Based on the findings of recent evidence of effectiveness of PrEP, in 2015 WHO
broadened and developed the consolidated HIV guidelines to all groups of population
incorporating MSM, IDUs, sex workers, transgender people, prisoners and other closed
settings who are at substantial risk of acquiring HIV infection (WHO, 2015). Offering
PrEP based on individual assessment rather than risk group is key factor in new
recommendations. New recommendations also focuses on PrEP to be given as an
additional prevention choice for people who are at substantial risk of HIV infection as
part of combination HIV prevention approaches (WHO, 2015). Thus, the new
recommendations facilitate a broader group of risk populations being positioned to
benefit from this additional prevention alternative.

Key Evidences
Cost-effectiveness
A number of studies have evaluated the cost–effectiveness of oral antiretroviral PrEP,
reporting results as the cost per infection averted, cost per life-year saved, cost per
quality-adjusted life-year gained, cost per disability-adjusted life-year (DALY) averted
and years on PrEP per infection averted (Hankins, 2014; WHO, 2015). A recent
systematic review of 13 of the cost–effectiveness studies for PrEP found that PrEP
could be a potentially cost-effective addition to HIV-prevention programs, particularly
when those at highest risk of HIV exposure are prioritized, that is, where HIV incidence
is highest. However, when the current price of drugs is high, as in Peru, PrEP may not
be reasonable even if it could have a significant impact among MSM (Gomez et al.,
2013). Studies have found PrEP to be cost-effective - depending on the cost of the drug

10

and delivery systems - when PrEP uptake is higher among people at substantial risk
(Grant et al., 2014). The results vary widely depending on epidemic type, location and
model parameters, including efficacy, cost, HIV incidence and target population (Alistar,
Grant, & Bendavid, 2014; WHO, 2015). For example, while PrEP could have impact in
key populations such as MSM, the first priority for PWIDs might be expanding access to
antiretroviral treatment (ART) and opioid substitution therapy. In considering trade-offs,
prioritizing PrEP for young women in southern Africa who are at alarmingly high risk of
HIV acquisition can be cost-effective, especially when there are costly obstacles to
recruiting HIV-positive people for treatment using the same drug (Hankins, Macklin, &
Warren, 2015).

Equity and Acceptability
Averting HIV infection among PrEP users will contribute to equitable health
outcomes by sustaining their health and the health of their sexual partners. Extending
PrEP recommendations beyond narrowly defined groups (such as MSM and serodiscordant couples) allows for more equitable access and will reduce future treatment
costs overall by preventing HIV infection in populations with a high incidence. PrEP
acceptability has been reported in multiple populations: women, sero-discordant
couples, female sex workers (FSWs), young women, PWID, transgender people,
service providers and MSM (Ayala et al., 2013; Brooks et al., 2012; Ferrer et al., 2016;
Frankis, Young, Lorimer, Davis, & Flowers, 2016; Galea et al., 2011b; Hosek et al.,
2013; Jayakumaran, Aaron, Gracely, Schriver, & Szep, 2016; Mensch, Van Der Straten,
& Katzen, 2012; Underhill et al., 2012; Van der Elst, Mbogua, Operario, Mutua, Kuo,
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Mugo, Kanungi, Singh, Haberer, & Priddy, 2013; Yang et al., 2013). Population support
for the provision of PrEP was based on the knowledge of safety and effectiveness and
the compatibility of PrEP with other prevention strategies (WHO, 2015).

Feasibility
Large scale PrEP trials focused on various population groups have proven
feasibility and safety in terms of administration among diverse trial settings and
demonstration projects (Baeten et al., 2012; Grant et al., 2014; Grohskopf et al., 2013;
Hosek et al., 2013; Marrazzo et al., 2015; Martin, Vanichseni, et al., 2014; Mayer et al.,
2015; Peterson et al., 2007; Rajchgot et al., 2016; Thigpen et al., 2012; Van Damme et
al., 2012). For example, the iPrEx OLE project and the Partners Demonstration project
both showed that PrEP implementation is feasible for different populations, including
men and women (Baeten et al., 2012; Choopanya et al., 2013). The PROUD study,
conducted in the United Kingdom and designed to mimic real-life settings, demonstrated
that PrEP is feasible and effective and is not associated with significant changes in
behavioral risk (McCormack & Dunn, 2015). Similarly, PrEP trials in Botswana, South
Africa, Thailand and the United States confirmed that protective levels of adherence are
feasible for most PrEP users (Bekker et al., 2015; Henderson et al., 2015; Holtz et al.,
2015; Liu, Cohen, Vittinghoff, & Anderson, 2015; Mannheimer, Hirsch-Moverman, &
Loquere, 2015), although challenges remain to achieve optimal PrEP adherence,
particularly among young people (Liu et al., 2015). Two placebo-controlled trials among
women found significant barriers to uptake and adherence (Marrazzo et al., 2015; Van
Damme et al., 2012). PrEP adherence among women has been high when open-label
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PrEP is provided (HPTN 067 ADAPT Study and the TDF2 Open Label Extension)
(Bekker et al., 2015; Thigpen et al., 2012).

Adherence to PrEP
Studies to date on daily oral PrEP indicate that medication adherence is the key
to achieving the maximum prevention benefit from HIV acquisition (Baeten et al., 2012;
Grant et al., 2014; Grohskopf et al., 2013; Marrazzo et al., 2015; Martin, Vanichseni, et
al., 2014; Peterson et al., 2007; Thigpen et al., 2012; Van Damme et al., 2012). A
recent review of the ART adherence studies over the past decade and adherence data
from completed PrEP trials suggests various approaches to effectively support
medication adherence (Koenig, Lyles, & Smith, 2013). These approaches include
educating patients about their medications; helping them anticipate and manage side
effects; helping them establish dosing routines that aligns with their work and social
schedules; providing reminder systems and tools; addressing financial, substance
abuse, or mental health needs that may impede adherence; and facilitating social
support (Amico, Mansoor, Corneli, Torjesen, & Van Der Straten, 2013; CDC, 2014;
Koenig, Lyles, & Smith; Tangmunkongvorakul et al., 2013; Ware et al., 2012).
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METHOD

Participants
Between June and July 2016, a convenience sample of 400 participants was
recruited at Connecticut’s largest MMP. Screening eligibility included: i) being 18 years
or older, ii) reporting HIV-uninfected, iii) reporting drug- or sex-related HIV risk
behaviors in the past 6 months, and iv) being able to understand, speak, and read
English. All patients were stabilized on methadone to treat opioid dependence. Among
the 438 MMP clients approached, 28 did not meet eligibility criteria and an additional 10
either did not agree to study participation or chose not to complete the entire survey,
leaving 400 individuals for the final analytical sample.

Study Setting and Procedures
We conducted a cross-sectional study of high-risk PWUD at Connecticut’s
largest addiction treatment program (APT Foundation, New Haven, Connecticut), which
provides opioid agonist treatments (methadone and buprenorphine) and clinical care to
over 7,000 opioid-dependent PWUD. Convenience sampling was used to recruit
participants through flyers, peers, word-of-mouth, and direct referral from counselors.
Screening was conducted by trained research assistants in a private room at APT
Foundation or by phone. Individuals who met inclusion criteria and expressed interest in
participating completed informed consent procedures in person and were administered
a 45-minute survey (range: 40 - 60 minutes) using an audio computer-assisted selfinterview (ACASI). All participants were reimbursed for the time and effort needed to
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participate in the survey. The study protocol was approved by the Institutional Review
Board at the University of Connecticut and received board approval from the APT
Foundation, Inc.

Measures
In addition to demographic and social characteristics, we assessed health
insurance status, visits to health care providers in the past 12 months and current
methadone dose. We assessed whether participants were prescribed any medication
(other than methadone) in the past 30 days and, for those who were, we assessed
medication adherence using a self-reported, validated three-item scale developed by
Wilson et al. (2016). Summary scales were calculated as the mean of the three
individual items with higher score indicating better adherence (0 – 100) (Wilson, Lee,
Michaud, Fowler, & Rogers, 2016).

Awareness and Willingness to Use PrEP
Participants were asked about their awareness and previous use of PrEP. Their
willingness to use PrEP was assessed after providing a brief description of PrEP
(Appendix). Participants were asked to respond to a statement “I would be interested in
taking PrEP to reduce my current risk of HIV infection” on a five-point Likert scale. Their
score was further dichotomized as “Yes” (strongly agree and agree) and “No” (strongly
disagree, disagree, and neutral). Some further hypothetical questions were asked to
assess participants’ anticipation of engaging in HIV risk reduction behaviors while on
PrEP: “How confident are you that you would always use condoms while on PrEP?”,
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and “How confident are you that you would stop sharing needles or works completely
while on PrEP?” The 5-point Likert response ranged from “Not at all confident” to
“Completely confident”. This variable was further dichotomized as “Yes” (completely
confident) and “No” (any other response, including being “not at all confident” to “very
confident”, but “not completely confident”). We chose to dichotomize these variables of
interest for better interpretability and simplicity and in order to be more conservative in
operationalizing the variables (i.e., consistently using condom and never sharing of
injection equipment).

Correlates of Willingness to Use PrEP
Covariate measures included were based on prior research (refs here**).
Neurocognitive impairment (NCI) was measured using the Brief Inventory of
Neurocognitive Impairment (BINI), which is a brief, 54-item self-reported measure of
neuropsychological symptoms (Copenhaver, Shrestha, Wickersham, Weikum, & Altice,
2016). The overall BINI score, which was obtained by summing responses to all items,
was converted to standardized scores (i.e., z-scores). Participants with a z-score ≥ 0.5
were classified as moderately to severely neurocognitively “impaired”, whereas those
with a z-score < 0.5 were classified as “not impaired” (Dwan, Ownsworth, Chambers,
Walker, & Shum, 2015). The overall internal consistency (Cronbach’s alpha) for the BINI
scale was 0.97. Depressive symptoms were assessed using the 20-item Center for
Epidemiological Studies Depression Scale (CES-D), with ≥16 indicative of moderate to
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severe depression (Radloff, 1977). The overall internal consistency (Cronbach’s alpha)
for the scale was 0.92.
Alcohol use disorders were measured using the validated 10-item Alcohol Use
Disorders Identification Test (AUDIT), with standard cut-offs ≥ 8 for men and ≥ 4 for
women suggestive of an AUD (Babor, Higgins-Biddle, Saunders, & Monteiro, 2001).
The overall international consistency for the AUDIT was 0.92. Current drug- and sexrelated risk was assessed for the past 30 days using an adapted version of the HIV risktaking behavior scale (HRBS) (Ward, Darke, & Hall, 1990). Risk perception for HIV was
measured by the question “What do you think your current risk of getting HIV is?” with
possible options being “no risk as all”, “moderate risk”, or “high risk”. Participants’
satisfaction with previous HIV prevention methods was assessed using the question
“Are you satisfied with your current method of HIV protection (e.g., condom use, clean
needle use)?”

Conjoint Analysis
We used full-profile conjoint analysis approach to assess the acceptability of
various hypothetical PrEP-related scenarios and to quantify the importance of key
hypothetical and known PrEP attributes on acceptability. Briefly, conjoint analysis is a
statistical technique often used to quantify consumer preferences for goods and
services. It enables researchers to test what combination of program attributes is most
critical in participants’ decision-making and which attributes are most preferred (Bridges,
2003; Ryan et al., 2001). It has been applied successfully to measure preferences in
economics and market research (Annunziata & Vecchio, 2013; Foxall, Menon, &
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Sigurdsson, 2016; Uchida, Onozaka, Morita, & Managi, 2014) and recently has gained
popularity in the health care studies (Bridges, Kinter, Kidane, Heinzen, & McCormick,
2008; Flynn, 2010; Kievit, Van Hulst, Van Riel, & Fraenkel, 2010; Lee, Newman,
Comulada, Cunningham, & Duan, 2012; Marshall, McGregor, & Currie, 2010).
Based on themes that emerged from prior studies on PrEP acceptability
(Eisingerich et al., 2012; Galea et al., 2011a; Shrestha, Altice, Karki, & Copenhaver,
2017; Wheelock et al., 2013) and input from PrEP experts, we composed six two-level
PrEP program design attributes that included: Cost (insurance covered vs. out-ofpocket), dosing (daily vs. on demand), efficacy level at preventing HIV (95% vs. 75%),
side-effects (none vs. nausea/dizziness), treatment setting (HIV clinic vs. drug treatment
clinic), and frequency of HIV testing needed (every 6 months vs. every 3 months) (Table
2).
A full-factorial design for six attributes, each with two levels, yielded 64 (26 = 64)
different PrEP program scenarios. Since asking participants to rate all 64 scenarios
would be difficult and burdensome, we used a fractional factorial orthogonal design
(Ryan, McIntosh, & Shackley, 1998) to generate a subset of all of the possible
combinations called an orthogonal array that allowed estimation of the part-worth
utilities for all main effects. Part-worth utility is the value respondents attach to a specific
level of a particular attribute. Relative importance reflects the influence of each attribute
on a participant’s decision-making. The ‘Generate Orthogonal Design procedure’ was
used to generate an orthogonal array and is typically the starting point of a conjoint
analysis. It is commonly used to reduce the number of profiles that have to be
evaluated, while ensuring enough data are available for statistical analysis, resulting in
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a carefully controlled set of "profiles" for the respondent to consider (Ryan et al., 1998).
This resulted in an orthogonal main effects design, thus yielding as much statistical
information as possible for estimating unbiased, precise preference parameters, such
as ensuring the absence of multicollinearity between attributes (i.e. attributes included in
the model are not correlated), equal preference weights in calculating efficiency. The
statistical procedure involved removing from the original set of 64, scenarios that were
linearly related to one other. We reduced the number of scenarios from 64 to 8 while
ensuring that all of the attribute/level combinations appeared with the same frequency.
The attributes were described in lay language with examples to aid
comprehension. Participants were then asked to rank the eight hypothetical PrEP
program scenarios (Figure 1) from 1 (“most likely to use”) to 8 (“least likely to use”),
which were presented concurrently, but none of the scenarios could share the same
value. The scenarios were presented in random order to prevent potential biases
related to order effects.

Data Analyses
All data analyses were performed using SPSS v. 23 (IBM Corp., 2015), and
statistical significance was set at p<0.05.

Awareness and Willingness to Use PrEP
We computed descriptive statistics, including frequencies and percentages for
categorical variables, and means and standard deviations for continuous variables.
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Correlates of Willingness to Use PrEP
After conducting bivariate analyses for significant associations of participants’
characteristics with their willingness to use PrEP, we conducted multivariate logistic
regression analyses on bivariate associations found to be significant at p<0.10. We
examined the correlates expressed as adjusted odds ratios (aORs) and their 95%
confidence intervals (95% CI). The final model was ultimately selected based on
goodness-of-fit using the Hosmer and Lemeshow Test (Hosmer, Hosmer, Le Cessie, &
Lemeshow, 1997).

Conjoint Analysis
We used conjoint analysis to assess the acceptability of hypothetical PrEP
scenarios and to quantify the impact of various PrEP attributes on acceptability. For the
first conjoint analysis exercise, the acceptability of each of the eight hypothetical PrEP
program scenarios was derived by averaging individual PrEP program acceptability
ratings across respondents. Ratings from each PrEP program was transformed into a
0–100 scale, whereby ‘‘highly likely would accept’’ = 100 and ‘‘highly unlikely would
accept’’ = 0. For the second conjoint analysis exercise, we used the “conjoint”
procedure that utilizes the rankings of the different PrEP program scenarios for each
participant to assess the impact of PrEP attributes. The conjoint procedure uses a set of
linear regressions to generate utility scores for each attribute level. The utility score,
called a part worth, is an estimate of the overall preference of utility associated with
each attribute level used to define the PrEP program. The utility score for each factor
level is analogous to regression coefficients and provide a quantitative measure of the
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preference for each factor level, with larger values corresponding to greater preference.
The relative importance score for each PrEP attribute provides a measure of how
important the attribute is to overall preference with greater score playing a more
significant role than those with smaller score. We expressed the utility scores on a
common scale in percentage terms. We then calculated the relative importance score
by taking the range of utility scores for any attribute levels (highest minus lowest),
dividing this by the sum of all the utility ranges, and multiplying by 100 (IBM Corp.,
2015; Ross, Avery, & Foss, 2003).
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RESULTS

Participant Characteristics
Among the 400 participants, the average age of the participants was 40.9 ± 11.1
years and 58.5% were male. Self-reported HIV risk behaviors were highly prevalent with
57.5% reporting recent drug injection (past 30 days) with two-thirds of these reporting
sharing needles/works. Of those who were sexually active (82.0%), 39.9% reported
having multiple sexual partners, yet 85.1% reported condom less sex with casual sexual
partners. Most participants reported having taken prescribed medication (other than
methadone) in the past 30 days, with a mean medication adherence score of 73.3
(SD=15.4) on a scale of 0–100. Approximately one-third of participants were classified
as being neurocognitively impaired, and 74.3% and 47.0% met screening criteria for
depression and AUDs, respectively. Self-reported HIV risk behaviors were highly
prevalent. Over half of participants reported being satisfied with their current method of
HIV prevention and two-thirds perceived that they were at risk of acquiring HIV.

Awareness and Willingness to Use PrEP
Only 18% of participants reported having heard of PrEP as a method to prevent
HIV transmission and 1.8% had ever used it. Conversations with friends (6.5%) and
health care providers (4.8%) were noted as the top sources of PrEP knowledge (Figure
1). Nearly two-thirds of participants (62.7%) reported that they would be willing to use
PrEP to reduce their risk of HIV infection. Participants willing to initiate PrEP were asked
about their anticipated sexual and drug-related risk behaviors while on PrEP, and only
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12.5% indicated that they would consistently use condoms while on PrEP. Regarding
drug-related risk, only 28.2% of participants reported that they would not share injection
equipment while on PrEP (Figure 1).

Correlates of Willingness to Use PrEP
While Table 2 shows the bivariate correlates of being willing to initiate PrEP,
Table 3 shows the independent correlates associated with this outcome in multivariate
modeling. Specifically, being neurocognitively impaired was associated with over a
three-fold odds (aOR=3.184, p=0.004) of being willing to initiate PrEP. Additionally,
compared to those who did not perceive themselves to be at risk for HIV, those with
moderate (aOR=4.439, p<0.001) and high (aOR=8.044, p<0.001) perceived risk were
significantly more likely to be willing to initiate PrEP.

Conjoint Analysis
PrEP acceptability ranged from 30.6% to 86.3% with a mean acceptability of
56.2% across the eight hypothetical PrEP program scenarios (Table 4). The PrEP
program scenario with the highest acceptability (scenario 1) had the following attributes:
lower cost (insurance covered), daily dosing, 95% effective, no side effects, prescription
at a HIV clinic, and HIV testing every 6 months.
When the eight PrEP attributes were examined individually, however, the
marginal utility for each attribute differed from the optimal program on several key
attributes when comparing the preferred versus the non-preferred attributes. The cost
associated with PrEP was the single most important attribute for participants.

23

Participants reported higher acceptability if the cost of PrEP was covered by insurance
(Marginal utility score: MUS=1.43), compared to paying out-of-pocket (MUS = -1.43),
yielding a net relative importance score (RIS) of 38.8. Efficacy of PrEP had the secondgreatest impact on PrEP acceptability. Participants reported higher acceptability for
PrEP when it was 95% effective (MUS=0.70) compared with 75% effective (MUS = 0.70), yielding a RIS of 20.5. Side effects had the third-greatest impact on PrEP
acceptability with an overall RIS of 11.9. There was a notable preference for PrEP with
no side effects (MUS = 0.29) compared to PrEP with even minor side effects (MUS = 0.29). Dosing frequency (RIS = 10.3), treatment location (RIS = 9.9), and frequency of
associated HIV testing (RIS = 8.3) had relatively low influence on PrEP acceptability.
Compared to taking PrEP on demand (MUS = -0.03), participants preferred taking PrEP
on a daily basis (MUS = 0.03). Receiving PrEP in drug treatment clinics (MUS = 0.19)
rather than in HIV clinics (MUS = -0.19) was preferred. The preferred frequency of
associated HIV testing was every 6 months (MUS = 0.02) as opposed to every 3
months (MUS = -0.02) (Table 5 and Figure 3).
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DISCUSSION

Given the dearth of literature examining the interest in or initiation of PrEP among
PWUD, we sought to directly assess this risk group for their willingness to use PrEP and
their perceptions about how PrEP might affect their drug and sexual risk behaviors.
Furthermore, we aimed to assess PrEP acceptability, as well as utilizing conjoint
analysis to quantify key attributes associated with PrEP acceptability in this key
population. Overall, several important findings were gleaned from this study that have
major implications for PrEP scale-up in MMP settings, where PrEP use among PWUD
was originally examined (Choopanya et al., 2013).
Almost none of our participants (<2%) had ever taken PrEP and few (18%) were
even aware of PrEP. This is especially concerning given that this is a population at highrisk for HIV, and who have frequent contact with various treatment providers (e.g.,
through MMPs and elsewhere). This represents missed opportunities to initiate, or at
least discuss, PrEP among PWUD. Limited PrEP awareness and use among PWUD
here is similar to that reported elsewhere among female sex workers in China (Peng et
al., 2012) and among other studies of PWUD in the U.S. (Kuo et al., 2016; Stein et al.,
2014), but PrEP awareness here was lower than that reported in studies of MSM (Ferrer
et al., 2016; Goedel et al., 2016; Hoagland et al., 2016; Young et al., 2013). The higher
level of knowledge about PrEP in MSM may stem from a number of PrEP initiatives that
have primarily focused on MSM and HIV sero-negative partners in sero-discordant
couples (Ware et al., 2012). Recent studies have also shown that many addiction
treatment providers, with whom MMP patients are in daily contact, have limited
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awareness of PrEP (Shrestha, Karki, Frederick, & Copenhaver, 2016; Spector, Remien,
& Tross, 2015). In the context of clinical settings, including MMP patients in this study,
treatment providers have great potential to engage their at-risk clients about PrEP
through counseling, referrals, research trials, and may also effectively promote
adherence to PrEP through counseling and monitoring. Our findings highlight the need
for ongoing training for MMP providers, so they can refer clients to PrEP and promote
PrEP adherence, as they would for other services (e.g., offer risk reduction items, HIV
testing, referral) relevant to HIV prevention.
When information deficits about PrEP were corrected by describing its potential
benefits, interest in initiating PrEP increased markedly, with nearly two-thirds (62.7%) of
participants being willing to initiate PrEP. Importantly, those who stand to benefit the
most from PrEP (i.e., those at highest risk for HIV) tended to be most interested in it.
Specifically, those who accurately perceived themselves as being at higher risk for
acquiring HIV were most willing to initiate it, as well as those with neurocognitive
impairment, which is associated with higher HIV risk behaviors (Anand, Springer,
Copenhaver, & Altice, 2010; Huedo-Medina, Shrestha, & Copenhaver, 2016; Shrestha
& Copenhaver, 2016a). Together, these findings support PrEP expansion for PWUD
enrolled in MMP.
The combination of high sex- and drug-related risk in MMP patients suggests that
PrEP would be ideal for this risk group, just as reported in the original PrEP trial among
PWID. In addition to the biomedical prevention benefits of PrEP, the structured nature of
MMPs and the requirement for regular counseling suggests that MMP settings could
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readily support the integration of PrEP into existing evidenced-based behavioral risk
reduction strategies.
Furthermore, we found that higher willingness to initiate PrEP was associated
with participants having NCI, which is highly prevalent (~30%) among this risk group
(Shrestha, Huedo-Medina, Altice, Krishnan, & Copenhaver, 2016). In prior studies
(Anderson, Higgins, Ownby, & Waldrop-Valverde, 2015; Attonito, Devieux, Lerner,
Hospital, & Rosenberg, 2014; Becker, Thames, Woo, Castellon, & Hinkin, 2011),
cognitive deficits have been associated with risky behaviors, poor medication
adherence, and treatment disengagement (Anand et al., 2010; Shrestha, HuedoMedina, & Copenhaver, 2015; Verdejo-Garcia & Perez-Garcia, 2007; Vo, Schacht,
Mintzer, & Fishman, 2014). Given the relationship between NCI and higher HIV risk
behaviors, this is an important group of PWUD who might benefit from PrEP. NCI may
also undermine the efficacy of PrEP since high levels of adherence are required for its
efficacy (Baeten et al., 2012; Choopanya et al., 2013; Grant et al., 2010; Shrestha,
Karki, Huedo-Medina, & Copenhaver, 2016; Thigpen et al., 2012; Van Damme et al.,
2012). For PWUD with NCI initiating PrEP, it is therefore crucial to couple PrEP with a
behavioral approach to support medication adherence, such as cues and reminders or
other cognitive remediation strategies (Barlati, Deste, De Peri, Ariu, & Vita, 2013; ColeLewis & Kershaw, 2010; Finitsis, Pellowski, & Johnson, 2014; Pop-Eleches et al., 2011).
Participants’ overall perception of HIV risk was relatively high in this cohort of
PWUD. We found that individuals who perceived themselves to be at higher risk of
contracting HIV reported greater willingness to initiate PrEP, which is consistent with
that reported in prior studies among MSM (Eisingerich et al., 2012; Golub, Gamarel,
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Rendina, Surace, & Lelutiu-Weinberger, 2013; Wheelock et al., 2013; Young et al.,
2013). The results suggest that participants are making rational judgments about their
own risk levels when considering whether to initiate PrEP. This may indicate not only be
a concern about risk of HIV infection but also a self-management response to their HIV
risk behaviors (Young et al., 2013). Thus, self-management programs, which have been
shown to have positive outcomes in a variety of long-term conditions (e.g., diabetes,
hypertension, arthritis) (Martin, Chinnock, et al., 2014), may be of specific usefulness to
promote self-management aspects of HIV prevention, such as HIV risk reduction
strategies and PrEP. Alternatively, PrEP may be seen as an important HIV prevention
approach in itself if, as our data suggest found, these individuals are unlikely to start
using condoms more consistently (Holt et al., 2012). Overall, our findings suggest the
need to consider how at-risk PWUD perceive and respond to their HIV risks as this may
have a significant impact on the development and roll-out of PrEP-related programs
targeting various risk populations.
Similar to other PrEP studies, findings here suggest that those who start PrEP
are unlikely to then modify their risk behaviors. While these data do not support risk
compensation as an anticipated behavioral response by PWUD, they do suggest that
this population is ideal for PrEP and opens opportunities for integrating biomedical and
behavioral interventions to enhance adherence and reduce other sexually transmitted
infections (STIs) and blood-borne viral infections. Despite variable findings from other
PrEP studies showing no risk compensation in clinical trials (Grant et al., 2010;
McCormack et al.; Molina et al., 2015) but elevated risk-taking in other observational
studies (Golub et al., 2013; Zhou et al., 2012), such responses should be closely
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examined in further PrEP studies in PWUD. Furthermore, prior studies have shown that
biomedical approaches to HIV prevention are optimized when they are combined with
evidence-based behavioral strategies including structural interventions that increase
access to services, decrease costs, and reduce stigma and discrimination to ensure
broad scale implementation, teaching HIV risk reduction and PrEP adherence skills,
routinely testing for HIV and STIs, and monitoring/supporting PrEP adherence over
time.
Results from our conjoint analysis reveal variations in participants’ attitudes and
preferences of PrEP attributes that collectively or individually may help to strengthen the
PrEP cascade (Liu et al., 2012). PrEP acceptability exceeded 80% for two case
scenarios. Two key attributes were central to both scenarios – low cost and high (95%)
efficacy – with other attributes varying between the two scenarios. It is not surprising
that low cost (PrEP covered by insurance) dominated the individual program attributes,
especially given the high unemployment level and 78% of the sample earning markedly
below the poverty level for Connecticut. This finding also aligns with that from previous
studies which identified cost as one of the major barriers to PrEP acceptability among
MSM, female sex workers, and male-to-female transgendered individuals (Brooks et al.,
2011; Galea et al., 2011a; Gersh et al., 2014; Schneider et al., 2010; Smith, Toledo,
Smith, Adams, & Rothenberg, 2012). It is encouraging, however, that most private and
public insurance plans in the U.S. cover the cost of PrEP, but this may be threatened if
the Affordable Care Act is repealed, potentially leaving over 20 million people without
insurance.
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Efficacy was the second most important attribute, with 95% efficacy, as
expected, being the preferred alternative, corroborating findings in Peru, a middleincome setting where patients must pay for their own medications (Galea et al., 2011a).
In addition, prior studies reported similar findings, where MSM were willing to use PrEP
with higher efficacy in preventing HIV (Golub, Kowalczyk, Weinberger, & Parsons, 2010;
Mustanski, Johnson, Garofalo, Ryan, & Birkett, 2013); no such studies exist for PWUD.
Notable here is while PrEP efficacy exceeds 90% in patients with high adherence,
efficacy falls markedly at lower adherence levels (Baeten et al., 2012; Choopanya et
al., 2013; Grant et al., 2010; Thigpen et al., 2012). While numerous factors contribute to
medication adherence (Fisher, Amico, Fisher, & Harman, 2008), mean adherence for
other medications in this sample was relatively low (Mean = 73.3). Prior research in this
population suggests a high level of neurocognitive impairment (NCI) (Shrestha &
Copenhaver, 2016b; Shrestha, Huedo-Medina, et al., 2016; Shrestha et al., 2015;
Shrestha, Karki, Huedo-Medina, & Copenhaver, 2017), which has been associated with
risky behaviors, poor medication adherence, and treatment disengagement (Anand et
al., 2010; Huedo-Medina et al., 2016; Shrestha et al., 2015; Verdejo-Garcia & PerezGarcia, 2007; Vo et al., 2014). Thus, NCI may undermine the effectiveness of PrEP if
prescribed to cognitively impaired individuals, since high levels of adherence to PrEPis
correlated with its efficacy (Baeten et al., 2012; Choopanya et al., 2013; Grant et al.,
2010; Shrestha, Karki, Huedo-Medina, et al., 2016; Thigpen et al., 2012; Van Damme
et al., 2012). One consideration for scaling up PrEP in PWUD would be to test and
introduce empirically-based strategies that simultaneously address NCI and medication
adherence to ensure higher PrEP efficacy. Alternatively, many more PrEP medications
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are being developed and tested, including injectable, long-acting medications that can
be administered once every 8-12 weeks (Landovitz, Kofron, & McCauley, 2016;
Markowitz et al., 2016). In the absence of such data about adherence to PrEP
medication and concomitant NCI, it may be beneficial to implement a combination HIV
prevention package that includes evidence-based HIV risk reduction and PrEP
adherence skills, routinely testing for HIV and STIs, and monitoring/ supporting PrEP
adherence over time.
Experiencing side effects like nausea and dizziness had the third greatest impact
on PrEP acceptability in the conjoint analysis. Not surprisingly, participants were
concerned about potential side effects from PrEP, opting for scenarios without them.
Previous studies have shown that potential side effects from PrEP medications as being
one of the major barriers to uptake (Galea et al., 2011a; Gersh et al., 2014; Mack,
Odhiambo, Wong, & Agot, 2014; Mustanski et al., 2013), yet numerous studies suggest
that currently approved PrEP medications have few to no side effects (Baeten et al.,
2012; Choopanya et al., 2013; Grant et al., 2010; Thigpen et al., 2012; Van Damme et
al., 2012). Strategies like informed or shared decision-making can be useful to help
guide patients to incorporate their preferences alongside evidence-based information in
their decisions about initiating a medication like PrEP (Elwyn et al., 2012; Elwyn,
Frosch, & Kobrin, 2016). To date, such decision aids are unavailable to at-risk
individuals and pre-PrEP counseling could provide clients with skills, strategies, and
support for minimizing adverse effects associated with taking PrEP (Van der Elst,
Mbogua, Operario, Mutua, Kuo, Mugo, Kanungi, Singh, Haberer, Priddy, et al., 2013).
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Low-threshold PrEP programs, however, may not have the luxury of extensive
counseling sessions, favoring brief, evidence-based decision aids.
Participants preferred to receive treatment at an addiction treatment program
(e.g., MMP) rather than a HIV clinic. Though not explored here, this finding may either
represent a convenience factor for patients who might prefer integrated or co-located
services (Sylla, Bruce, Kamarulzaman, & Altice, 2007), or alternatively, they perceived
high levels of HIV stigma by attending such sites, even though they do not have HIV.
For patients who preferred this attribute, there may be multiple advantages, including
either combining supervised of methadone and PrEP medication, which has been
successfully done for other diseases (Batki, Gruber, Bradley, Bradley, & Delucchi, 2002;
Bruce et al., 2012; Litwin et al., 2009; Morozova, Dvoryak, & Altice, 2013; O'Connor et
al., 1999), or when not feasible, to take advantage of the regular interaction with clinical
staff supervising methadone administration to inquire about adherence and provide brief
counseling when needed. Although HIV and TB services have been successfully
integrated into addiction treatment settings (Bachireddy et al., 2014; Haddad, Zelenev,
& Altice, 2013), further research is needed to ascertain the feasibility of integrating PrEP
into such settings.
Consistent with national recommendations, participants in this study preferred
PrEP to be taken on a daily basis, regardless of event-level risk-taking that would
support PrEP taken on-demand only as needed. On-demand PrEP has only been
documented to be effective in reducing HIV transmission only in MSM. Daily PrEP,
however, is efficacious among all key populations (Baeten et al., 2012; Choopanya et
al., 2013; Grant et al., 2010; Thigpen et al., 2012; Van Damme et al., 2012). This
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finding aligns well with their interest in receiving PrEP at addiction treatment settings,
like MMPs, where there is the potential for integration of services and daily supervision.
Though integrating HIV testing at addiction treatment settings is an evidence-based
practice (Metsch et al., 2012), many real-world treatment settings do not integrate such
practices, preferring to refer offsite for either logistical or staffing reasons (Chadwick,
Andrade, Altice, & Petry, 2014). Last, our sample generally preferred minimal testing
and low levels of interaction with their healthcare provider. The desired frequency of HIV
testing while on PrEP was every six months in this sample, similar to previous studies
(Eisingerich et al., 2012; Wheelock et al., 2013), but inconsistent with national
guidelines that recommend side-effect monitoring and testing for HIV and sexually
transmitted infections every three months (CDC, 2014; WHO, 2015). Where guidelines
are discordant with patient preferences, however, uptake or retention may be
suboptimal, especially in PWUD who are presently uninformed about PrEP. In tailoring
programs for this population, designing better PrEP program with brief follow-up calls or
texting strategies may address their concerns about more frequently monitoring.
Our data further indicated that participants were willing to make trade-offs in
exchange for having the PrEP program they prefer. For example, participants were
willing to attend a HIV clinic or accept PrEP with lower efficacy to avoid side effects (i.e.,
nausea, dizziness) associated with PrEP. In other instances, participants were willing to
pay out-of-pocket in exchange for a 20% increase in PrEP efficacy from 75% to 95%.
Much has been learned from PrEP demonstration programs targeting MSM (Cohen et
al., 2015; Hosek et al., 2017; Liu et al., 2014; Liu, Cohen, Vittinghoff, & et al., 2016), and
many such lessons might be applied to PWUD, but nonetheless, the PrEP cascade will
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be optimized, including satisfaction, if patient preferences are incorporated into
treatment decision-making process.

Study Limitations
Our overall findings are not without limitations. As with all cross-sectional studies,
we are only able to assess associations between variables rather than causal
relationships. The use of self-reported measures may have resulted in participant
underreporting of socially undesirable behaviors (e.g., drug- and sex-related risk
behaviors) or inconsistently reporting (e.g., HIV status) because of stigma or fear of
judgment. Additionally, our use of self-report measures may have resulted in participant
underreporting or inconsistent reporting (e.g., HIV status) of socially undesirable
behaviors. Although a brief explanation about PrEP was provided, we do not know the
extent to which participants understood every attribute/aspect of PrEP (e.g.,
effectiveness, cost, side-effects, dispensing venue, adherence, etc.) when ranking the
PrEP program scenarios and/or providing responses regarding their willingness to
initiate PrEP. The participants in this study were high-risk PWUD enrolled in MMP; thus,
our findings may not be generalizable to PWUD in other settings. PrEP characteristics
modelled in our analysis did not include factors such as perception of HIV risk, trust in
health care providers, stigma and discrimination, or satisfaction with current HIV
prevention methods, which could also impact PrEP acceptability. We dichotomized our
variables of interest (e.g., willingness to use PrEP), which may have resulted in the loss
of some valuable information during the process. Finally, the use of the BINI, although a
very user-friendly and convenient screening instrument for difficult-to-reach populations,
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is not designed to measure as many cognitive domains as a comprehensive battery of
tests.
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SUMMARY AND FUTURE IMPLICATIONS

PrEP represents an important biomedical innovation in evidence-based primary
HIV prevention among key risk populations. Although PWUD are one of the key risk
populations who could benefit from the use of PrEP (CDC, 2014; Shrestha, Karki, Altice,
et al., 2017; WHO, 2015), there have been no published studies conducted
incorporating the use of PrEP into HIV prevention approaches targeting this
underserved group. As part of our formative work, we conducted this study to
understand whether high-risk PWUD are interested in taking PrEP and how these
individuals value various aspects of PrEP treatment. As such, this study investigated the
acceptability of PrEP based on a number of known PrEP attributes and factors related
to willingness to use PrEP among high-risk PWUD in an addiction treatment setting. To
our knowledge, this is also the first study to utilize conjoint analysis procedure to
examine the preferences and future acceptability of attributes of PrEP program among
high-risk PWUD in the context of a substance abuse treatment setting. Key findings
include low knowledge about PrEP, but when informed, high levels of PrEP acceptability
if PrEP delivery programs for PWUD are optimally designed. Findings further suggest
that PWUD who would benefit from PrEP most were those most interested in receiving
it. Moreover, the structured setting of MMPs provides an ideal clinical context in which
to integrate biomedical and behavioral interventions in order to optimize HIV prevention
efforts. The findings from this study provide preliminary evidence in support of the
development and implementation of a PrEP program integrated into existing evidencebased HIV prevention efforts that target high risk PWUD. This will help guide
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implementation of PrEP among high-risk PWUD in the context of common drug
treatment settings and has the potential to significantly improve the PrEP continuum of
care. Future studies are warranted to investigate the actual uptake of PrEP and to
implement evidence-based interventions to improve PrEP continuum of care among this
underserved population.
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Table 1: Characteristics of the participants (N = 400)
Variable

Frequency

Age: Mean (±SD)
Gender
Male
Female
Sexual orientation
Heterosexual or straight
Homosexual, gay, or lesbian
Bisexual
Ethnicity
White
African American
Hispanic or Latino
Other
Marital status
Married
Divorced
Widowed
Single
High school graduate
Employed
Annual Income
< $10,000
$10,000 - $19,999
≥ $20,000
Injected drugs (past 30 days)
Shared needles/works (past 30 days)
No
Yes
Sexually active (past 30 days)
Number of sexual partners (past 30 days)
1
2–5
≥6
Always used condom with casual partner
No casual partner
No
Yes
Taking prescribed medication
Medication adherence: Mean (SD)
Heard about PrEP
Ever taken PrEP

40.9 (11.1)
234
166

58.5
41.5

345
16
39

86.3
4.0
9.7

253
70
61
16

63.2
17.5
15.3
4.0

83
111
14
192
293
69

20.8
27.8
3.5
48.0
73.3
17.3

312
57
31
230
n = 230
80
150
328
n = 328
197
116
15
n = 328
64
215
49
308
73.3 (15.4)
72
7

78.0
14.2
7.8
57.5

Legend: SD: standard deviation; PrEP: pre-exposure prophylaxis

63

%

34.8
65.2
82.0
60.0
35.4
4.6
19.5
65.6
14.9
77.0
18.0
1.8

Table 2: Characteristics of participants and HIV transmission risk behaviors, stratified by
their willingness to use PrEP
Willingness to use
Variables
Characteristics of participants
Age: Mean (SD)
Gender
Male
Female
Sexual orientation
Heterosexual or straight
Homosexual, gay, or lesbian
Bisexual
Ethnicity
Non-white
White
Marital status
Married
Divorced
Widowed
Single
High school graduate
No
Yes
Employed
No
Yes
Income level
< $10,000
$10,000 - $19,999
≥ $20,000
Currently have health insurance
No
Yes
Visited healthcare provider (past 12 months)
No
Yes
Homeless (past 12 months)
No
Yes
Methadone dose: Mean (SD), mg
Taking medication (past 30 days)
No
Yes
Medication adherence: Mean (SD)
Ever heard of PrEP
No
Yes
Neurocognitive impairment
No
Yes
Moderate to Severe Depression
No
Yes
Alcohol use disorders
No

OR (95% CI)

p

No
(n = 149)

Yes
(n = 251)

39.7 (11.4)

41.8 (10.8)

1.017 (.999, 1.037)

0.070

94 (23.5)
55 (13.8)

140 (35.0)
111 (27.8)

1.355 (.894, 2.053)

0.152

137 (34.3)
5 (1.3)
7 (1.8)

208 (52.0)
11 (2.8)
32 (8.0)

1.449 (.493, 4.262)
3.011 (1.292, 7.015)

0.500
0.011

44 (11.0)
105 (26.3)

103 (25.8)
148 (37.0)

.602 (.391, .928)

0.022

32 (8.0)
33 (8.3)
4 (1.0)
80 (20.0)

51 (12.8)
78 (19.5)
10 (2.5)
112 (28.0)

1.483 (.813, 2.705)
1.569 (.454, 5.426)
.878 (.519, 1.488)

0.199
0.477
0.630

32 (8.0)
117 (29.3)

75 (18.8)
176 (44.0)

.642 (.399, 1.032)

0.067

277 (69.3)
51 (12.8)

54 (13.5)
18 (4.5)

1.054 (.615, 1.807)

0.848

254 (63.5)
52 (13.0)
22 (5.5)

58 (14.5)
5 (1.3)
9 (2.3)

.727 (.410, 1.288)
1.032 (.478, 2.232)

0.274
0.935

15 (3.8)
313 (78.3)

4 (1.0)
68 (17.0)

.768 (.286, 2.066)

0.601

29 (7.2)
299 (74.8)

5 (1.3)
67 (16.8)

1.198 (.586, 2.449)

0.621

172 (43.0)
156 (39.0)
81.3 (29.9)

26 (6.5)
46 (11.5)
81.3 (27.4)

1.252 (.834, 1.879)
1.000 (.993, 1.007)

0.278
0.982

38 (9.5)
111 (27.8)
75.4 (15.8)

54 (13.5)
197 (49.3)
72.2 (15.2)

1.249 (.776, 2.010)
.986 (.970, 1.002)

0.360
0.076

120 (30.0)
29 (7.2)

208 (52.0)
43 (10.8)

.855 (.508, 1.441)

0.558

122 (30.5)
27 (6.8)

157 (39.3)
94 (23.5)

2.705 (1.659, 4.411)

<0.001

48 (12.0)
101 (25.3)

55 (13.8)
196 (49.0)

1.694 (1.074, 2.671)

0.023

87 (21.8)

125 (31.3)

-

-
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Yes
HIV transmission risk behaviors
During the past 30 days…
Injected drugs
No
Yes
Shared injection equipment
No
Yes
Had sex
No
Yes
Number of sexual partners
1
2–5
≥6
Always used condom with regular partner
No
Yes
Always used condom with casual partner
No
Yes
Diagnosed with STIs (past 12 months)
No
Yes
Perceived risk for HIV infection
No risk at all
Moderate
High
Satisfied with current method of HIV prevention
No
Yes

62 (15.5)

126 (31.5)

1.437 (.940, 2.129)

0.097

72 (18.0)
77 (19.3)

98 (24.5)
153 (38.3)

1.460 (.969, 2.198)

0.070

32 (13.9)
45 (19.6)

48 (20.9)
105 (45.7)

1.556 (.882, 2.744)

0.127

28 (7.0)
121 (30.3)

44 (11.0)
207 (51.7)

1.089 (.645, 1.839)

0.751

83 (25.3)
35 (10.7)
3 (0.9)

114 (34.8)
81 (24.7)
12 (3.7)

1.685 (1.035, 2.742)
2.912 (.797, 10.647)

0.036
0.106

105 (34.1)
8 (2.6)

177 (57.5)
18 (5.8)

1.335 (.561, 3.177)

0.514

80 (30.3)
12 (4.5)

135 (51.1)
37 (14.0)

1.827 (.901, 3.707)

0.095

128 (32.0)
21 (5.3)

218 (54.5)
33 (8.3)

.923 (.512, 1.663)

0.789

65 (16.3)
57 (14.2)
27 (6.8)

64 (16.0)
88 (22.0)
99 (24.8)

1.568 (.970, 2.533)
3.724 (2.153, 6.441)

56 (14.0)
93 (23.3)

106 (26.5)
145 (36.3)

.824 (.544, 1.248)

0.065
<0.001
0.360

Legend: PrEP: Pre-exposure prophylaxis; SD: Standard deviation; OD: Odds ratio; STIs: Sexually transmitted
infections; OR: Odds ratio
Note: STIs in the past 12 months

65

Table 3: Multivariate logistic regression models of factors associated with willingness to
use PrEP
Willingness to use PrEP

Variables

aOR
95% CI
P
Age
1.017
.986, 1.049
0.280
Sexual orientation
Heterosexual or straight
Homosexual, gay, or lesbian
1.378
.279, 6.814
0.694
Bisexual
2.920
.930, 9.171
0.067
Ethnicity
Non-white
White
1.188
.566, 2.496
0.648
High school graduate
No
Yes
1.040
.482, 2.240
0.920
Neurocognitive impairment
No
Yes
3.184
1.459, 6.949
0.004
Moderate to Severe Depression
No
Yes
1.219
.535, 2.779
0.638
Alcohol use disorders
No
Yes
1.023
.526, 1.986
0.948
Injected drugs
No
Yes
.986
.483, 2.012
0.968
Number of sexual partners
1
2–5
.714
.350, 1.455
0.353
≥6
.629
.126, 3.139
0.572
Always used condom with casual partner
No
Yes
3.401
.940, 6.307
0.062
Perceived risk for getting HIV
No risk at all
Moderate
4.439
1.959, 7.060 <0.001
High
8.044 3.012, 13.481 <0.001
Hosmer and Lemeshow Test: Chi-square = 5.439; p = 0.710

Legend: aOR: Adjusted odds ratio
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Table 4: Acceptability (Mean) of hypothetical pre-exposure prophylaxis (PrEP) scenarios with different attributes in order
of decreasing acceptability among participants
PrEP Attributes

PrEP
Scenarios

PrEP Acceptability
Mean

Cost

Dose

Efficacy

Side Effects

Treatment Location

HIV Testing Needed

1

86.28

Insurance covered

Daily use

95%

None

HIV clinic

Every 6 months

2

82.09

Insurance covered

On demand

95%

Nausea/Dizziness

Drug treatment clinic

Every 3 months

3

70.75

Insurance covered

Daily use

75%

None

Drug treatment clinic

Every 3 months

4

57.25

Insurance covered

On demand

75%

Nausea/Dizziness

HIV clinic

Every 6 months

5

51.44

Out of Pocket

On demand

95%

None

Drug treatment clinic

Every 6 months

6

39.84

Out of Pocket

Daily use

95%

Nausea/Dizziness

HIV Clinic

Every 3 months

7

31.63

Out of Pocket

On demand

75%

None

HIV clinic

Every 3 months

8

30.56

Out of Pocket

Daily use

75%

Nausea/Dizziness

Drug treatment clinic

Every 6 months
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Table 5: Relative importance and marginal utilities of PrEP attribute levels among
participants
Attributes
Cost
Efficacy
Side-effects
Dosing
Treatment location
HIV testing needed

Attribute Levels
Insurance Covered
Out of pocket
95%
75%
None
Nausea/dizziness
Daily use
On demand
Drug treatment clinic
HIV clinic
Every 6 months
Every 3 months

Relative Importance
Score (%)
38.8
20.5
11.9
10.3
9.9
8.3

Legend: PrEP: pre-exposure prophylaxis, RIS: relative importance score
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Figure 1: Variables of interest related to PrEP among participants (N = 400)
98.3
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62.7
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30
18

20
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1.8

1.3

Website

5.3

2.8

1.5

Newspaper

0.5

HIV counselor

4.8
1.3

Community meeting

6.5

Work colleague

10

1.8

Ever heard of
PrEP

Source of PrEP knowledge

Ever used PrEP
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Willingness to
initiate PrEP

Yes

No

Yes

No

Yes

No

Yes

No

Other

Healthcare provider

Family member

Friend

Yes

No

0

Anticipation of Anticipation of not
consistent
sharing injection
condom use while equipment while
on PrEP
on PrEP

Figure 2: Example of full-profile conjoint task (hypothetical PrEP program scenarios)
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Figure 3: Marginal utilities of pre-exposure prophylaxis (PrEP) attributes’ levels among participants

Legend: PrEP: pre-exposure prophylaxis
* Constant: 4.467 (0.110)
Pearson’s R: 0.998
Kendall’s tau: 1.000
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Table 1: Summary of Guidance for PrEP Use
Heterosexual Men and
Injection Drug Users
Women
HIV-positive sexual
• HIV-positive sexual
• HIV-positive injecting
partner
partner
partner
Recent bacterial STI
• Recent bacterial STI
• Sharing needles and
works
Multiple sexual partners
• Multiple sexual partners
• Recent drug treatment
History of inconsistent
• History of inconsistent
(but currently injecting)
or no condom use
or no condom use
Commercial sex work
• Commercial sex work
• High-prevalence area
Documented negative HIV test result before prescribing PrEP
No signs/symptoms of acute HIV infection
Normal renal function; no contraindicated medications
Documented hepatitis B virus infection and vaccination status

Men Who Have Sex with Men
•
Detecting
Substantial Risk
of Acquiring HIV
Infection

•
•
•
•

Clinically
Eligible

•
•
•
•

Daily, continuing, oral doses of TDF/FTC (Truvada), ≤90-day supply

Prescription

Other Services

Follow-up visits at least every 3 months to provide:
• HIV test, medication adherence counseling, behavioral risk reduction support.
• Side effect assessment, STI symptom assessment
• At 3 months and every 6 months thereafter, assess renal function
• Every 6 months, test for bacterial STIs
•

•
Do oral/rectal STI
testing

•

Assess pregnancy
intent
Pregnancy test every 3
months
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•

Access to clean
needles/syringes and
drug treatment services

Table 2: Outcomes from Various PrEP RCTs
Protective Effect
All Study Participants

Protective Effect
Participants with Higher Adherence

62% - 76%

Up to 90%

Gay men and other MSM (iPrEX study): Brazil, Ecuador,
Peru, South Africa,
Thailand and the United States

44%

90%

People who inject drugs (Bangkok Tenofovir Study)

49%

75%

FEM-PrEP: heterosexual women in Kenya, South Africa
and the United Republic of Tanzania

<30% adherence, no effect

<30% adherence, no effect

VOICE heterosexual women in South Africa, Uganda and
Zimbabwe

<30% adherence, no effect

<30% adherence, no effect

Study & Population
Heterosexual men and women (Partners PrEP; TDF-2
study): Botswana, Kenya and Uganda
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Brief description of pre-exposure prophylaxis (PrEP) provided to the participants
“There is a new way to prevent HIV infection for people who may be exposed to the
virus. It is called Pre-Exposure Prophylaxis or PrEP. It involves an HIV-negative person
taking a pill daily, on an ongoing basis (starting before an exposure and continuing after
for as long as the person is at risk) to reduce their risk of HIV infection. Research
suggests that PrEP is generally safe and is highly effective (over 90%) in preventing
HIV infection if taken every day. It is much less effective if not taken every day and does
not protect against other sexually transmitted infections. Taking PrEP would require a
visit to a doctor every three months in order to be tested for HIV, STIs and side effects.”
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Flyer
University of Connecticut
Volunteers Wanted for a Research Study
Improving health care services during drug treatment
We are conducting a research study to assess what people think of Pre-Exposure Prophylaxis
(PrEP) and how familiar people are with various kinds of communication technologies (i.e., landline
phone, cell phone, and internet) and what tools would be the most helpful while in treatment to keep
track of medical appointments or help remember to take medications. Upon meeting criteria, you will
have to complete a survey that will take approximately 40-45 minutes.
You may be eligible to participate if ALL of the following apply to you:
• You are 18 years or older
• You are HIV-negative
• You are enrolled in methadone maintenance program
• You are available to participate in a survey
• You are able to understand, speak, and read English.
Participants will receive reimbursement for $25 for completing the survey.
To learn more about this research, please contact:
Brian, Jen, or Roman (Phone #: (203)-781-4690)
This research is conducted under the direction of Dr. Michael Copenhaver, Department of Allied
Health Sciences, University of Connecticut.
UConn Protocol # H16-116
Research Study
UConn Protocol # H16-090
Contact Brian, Jen, or Roman

Phone #: 203-781-4690

Research Study
UConn Protocol # H16-090
Contact Brian, Jen, or Roman

Phone #: 203-781-4690

Research Study
UConn Protocol # H16-090
Contact Brian, Jen, or Roman

Phone #: 203-781-4690

Research Study
UConn Protocol # H16-090
Contact Brian, Jen, or Roman

Phone #: 203-781-4690

Research Study
UConn Protocol # H16-090
Contact Brian, Jen, or Roman

Phone #: 203-781-4690

Research Study
UConn Protocol # H16-090
Contact Brian, Jen, or Roman

Phone #: 203-781-4690
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Informed Consent
Consent Form for Participation in a Research Study

Principal Investigator: Dr. Michael Copenhaver
Student Researcher: Roman Shrestha
Study Title: HIV prevention and PrEP adherence among high-risk drug users
Sponsor: National Institute on Drug Abuse
Introduction
First of all, thank you for taking the time to look over this invitation to participate in our study. You
are invited to participate in a research study designed to provide us with information to improve our
HIV prevention services. We are interested in hearing how familiar you are with a new treatment,
Pre-exposure Prophylaxis (PrEP), and whether you believe that PrEP would be helpful as part of
HIV prevention series while you are in drug treatment. We are also interested in hearing your
opinion about the kinds of communication technologies (i.e., landline phone, cell phone, and
internet) that you think may be helpful for you to use to support your health care while you are in
drug treatment (e.g., medical appointment reminders). You have been asked to participate
because you are HIV-negative and currently enrolled in drug treatment at the APT Foundation.
In order to decide whether or not you want to be a part of this study, you should know enough
about its risks and benefits to make an informed decision. This consent form gives you detailed
information about the study, which a member of the research team will discuss with you. This
discussion should go over all aspects of this research: its purpose, the procedures that will be
performed, any risks of the procedures, and potential benefits. We also encourage you to ask
questions now and at any time. Once you understand the study, you will be asked if you wish to
participate; if so, you will be asked to sign this consent form, and you will be given a copy.
Why is this study being done?
The purpose of this research study is to hear your opinion about some ways to improve our HIV
prevention services. We want to know how helpful you think the use of pre-exposure
prophylaxis (PrEP) would be as part of HIV prevention in drug treatment, how familiar you are
with various kinds of communication technologies (i.e., landline phone, cell phone, and internet),
and what tools would be the most helpful while you’re in drug treatment to keep track of when
you have medical appointments or need to take medications.
What are the study procedures? What will I be asked to do?
If you agree to take part in this study, you will be asked to participate in a survey that ask you to
answer questions about your knowledge and suggestions about PrEP, whether you own and
use various communication devices (e.g., cell phone, smart phones), your use of the internet, as
well as questions about memory challenges you may experience that may be improved by using
communication devices while in drug treatment. The survey will last between 40-45 minutes and
will be held in a private room at the APT Foundation.
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What are the risks or inconveniences of the study?
We believe there are no known risks associated with this research study; however, a possible
inconvenience may be the time it takes to complete the study and the possibility of experiencing
discomfort regarding questions related to drug use and sexual risk behaviors in the survey. You
are free not to answer such questions and also to withdraw yourself from participating in the
research process at any time you like to do so.
If you would like to talk to a counselor about your feelings at any time, we can connect you with
a counselor at the APT Foundation.
What are the benefits of the study?
You may not directly benefit from this research; however, we hope that your participation in the
study may assist researchers to understand whether it will one day be helpful for care providers
to develop PrEP programs and use communication technology (e.g., cell phone, smartphone) to
help you remember things like when to take medications, come to medical appointments, and to
get more out of your health care.
Will I receive payment for participation? Are there costs to participate?
Your participation is purely voluntary. There are no costs and you will be paid $25 in cash after
the completion of the survey.
How will my personal information be protected?
We will make every effort to insure your privacy and confidentiality. If you do not choose to
participate in this study, all information that you have given us will be destroyed immediately. If you
do choose to participate, in all of our study records, you will be identified by a number and your
name will be known only to the researcher. Your name will not appear in any publication or be
released to anyone without your written consent. You should understand, however, that there is a
risk that you will be recognized by other patients or staff involved in the study and that you may be
recognized as a participant in a research program. But this is no greater than the usual risk of
identification that occurs in your clinical care.
The following procedures will be used to protect the confidentiality of your data. The researchers
will keep all study records (including any codes to your data) locked in a secure location.
Research records will be labeled with a code. The code will be derived from a number (e.g.
“sequential 3 digit code) that reflects how many people have enrolled in the study. A master key
that links names and codes will be maintained in a separate and secure location. The master key
will be destroyed after 3 years after the completion of this study. All electronic files (e.g., database,
spreadsheet, etc.) containing identifiable information will be password protected. Any computer
hosting such files will also have password protection to prevent access by unauthorized users.
Only the members of the research staff will have access to the passwords. Data that will be
shared with others will be coded as described above to help protect your identity. At the conclusion
of this study, the researchers may publish their findings. Information will be presented in summary
format and you will not be identified in any publications or presentations.
Data that we collect from you may be shared with other researchers in the future, but only after
your name and all identifying information have been removed.
We will do our best to protect the confidentiality of the information we gather from you but we
cannot guarantee 100% confidentiality. Your confidentiality cannot be guaranteed if your record is
subpoenaed in a court of law or in the event the researcher determines that you are a clear and
imminent danger to yourself and/or others. In addition, confidentiality cannot be guaranteed if you
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disclose that you are intending to or currently sexually or physically abusing a child or an elderly
person.
You should also know that the UConn Institutional Review Board (IRB) and Research Compliance
Services may inspect study records as part of its auditing program, but these reviews will only
focus on the researchers and not on your responses or involvement. The IRB is a group of people
who review research studies to protect the rights and welfare of research participants.
Can I stop being in the study and what are my rights?
You do not have to be in this study if you do not want to. If you agree to be in the study, but later
change your mind, you may drop out at any time. There are no penalties or consequences of any
kind if you decide that you do not want to participate. You do not have to answer any question that
you do not want to answer.
Whom do I contact if I have questions about the study?
Take as long as you like before you make a decision. We will be happy to answer any question you
have about this study. If you have further questions about this study or if you have a researchrelated problem, you may contact the principal investigator, Dr. Michael Copenhaver at (860)
486-2846 or the student researcher, Roman Shrestha at (203) 781-4690. If you have any
questions concerning your rights as a research participant, you may contact the University of
Connecticut Institutional Review Board (IRB) at 860-486-8802.
Documentation of Consent:
I have read this form and decided that I will participate in the project described above. Its
general purposes, the particulars of involvement and possible risks and inconveniences have
been explained to my satisfaction. I understand that I can withdraw at any time. My signature
also indicates that I have received a copy of this consent form.

____________________
Participant Signature:

____________________
Print Name:

__________
Date:

____________________
Signature of Person
Obtaining Consent

____________________
Print Name:

__________
Date:
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Screening Form
Screening Questionnaires
Interviewer:

____________________________

Client name: ____________________________

Date:

_________________

Contact:

_________________

1. Are you enrolled at the APT Foundation drug treatment program? Y_______ N ________
If No, where? ________________________________
Dose _________

2. Are you a physician, counsellor, or other health care provider working with patients enrolled
at the APT Foundation? Y____ N ____
If No, where? ________________________________

3. Do you currently drink alcohol? ________

(If yes, how much?)

4. Do you have children? _______________

(If yes) Do you have custody? _________

5. Do you live in New Haven? ______________

(If no, where)? _____________________

_________________

6. Do you have reliable transportation? _________
7. Have you ever been tattooed?

___________

8. What is the highest level of school that you have completed? _________________
9. Have you ever been tested for HIV? ________
What year was the most recent test? _______
What was the result of the test? ___________

10. Have you seen a psychiatrist in the past 6 months? ____
If yes, for what?

Depression ___

PTSD ______ Schizophrenia __________

Bipolar_______

Anxiety _____

If other, explain _____________

11. Are you currently suicidal or homicidal? ______
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Other__________________

Survey Questionnaires
Demographics
1. Interviewer: ______________________
2. Research staff, please fill in the participant number. _____
3. What year were you born? Please enter the four-digit year _____
4. What is your age? _____
5. What is your gender?
a. Male
b. Female
c. Transgender
6. What is your sexual orientation?
a. Heterosexual or straight
b. Homosexual, gay, queer, or lesbian
c. Bisexual
d. Other
7. Which best describes you?
a. White
b. African American or Black
c. Hispanic or Latino
d. Asian or Pacific Islander
e. Other
8. What is your current marital status?
a. Now married or living with partner
b. Divorced
c. Separated
d. Widowed
e. Never married
9. What is the highest level of education you have completed?
a. Middle School (Jr. High School) or Less
b. Some High School, No Diploma
c. High School Graduate / GED or Equivalent
d. Junior (2-year) College
e. Technical / Trade / Vocational School
f. Some College (4-year college or university)
g. College Graduate (4-year college or university)
10. What is your primary language?
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a. English
b. Spanish
c. Other
11. What is your employment status?
a. Working now (this includes full time work, part time work)
b. Only temporarily laid off, sick leave or maternity leave
c. Unemployed and looking for work
d. Retired
e. Disabled, permanently or temporarily
f. Keeping house (full-time homemaker)
g. Student
h. Unemployed and not looking for work (not disabled or on medication)
i. Other
12. Which is closest to your current income?
a. Under $10,000
b. $10,000 to $19,999
c. $20,000 to $29,999
d. $30,000 or more
13. Do you have health insurance?
1. No
2. Yes
14. What type of coverage do you have?
a. Private health insurance
b. Medicare
c. Medi-gap
d. Medicaid
e. SCHIP
f. Military healthcare
g. Indian Health Service
h. State Sponsored Plan
i. Other government plan
j. Single service plan
k. Alliance
l. Other coverage
m. No coverage
15. Have you seen a doctor, nurse, or other health care provider in the past 12 months?
1. No
2. Yes
16. In the past 12 months, have you been homeless at any time? By homeless, I mean you
were living on the street, in shelter, in a single room occupancy hotel, or in a car.
1. No
2. Yes
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17. Are you currently homeless?
1. No
2. Yes
18. Are you currently on methadone maintenance program?
1. No
2. Yes
19. What is your current methadone dose? _____
20. What do you often use to help you remember take your medication?
a. Pillbox
b. Alarm
c. Take it at the same time each day
d. Ask family and friends
e. Use a pill calendar or drug reminder chart
f. Leave notes to remind yourself
g. Email or calendar reminder
h. Nurse call
i. Text service
j. None
Communication Technology and mHealth Scale
I.

Access to and Frequency of Use of Communication Technology

1. Do you own or have access to the following devices on a daily basis (check all that apply)?
a.
b.
c.
d.
e.
f.
g.

Landline telephone
Cell phone (without internet access)
Cell phone (with internet access, i.e. a Smartphone)
Tablet (e.g., iPad, Samsung Galaxy Tab, Kindle Fire etc.)
Laptop
Personal Computer (PC)
Other devices (please write all other type of communication/mobile devices you own
or have daily access to; e.g.,Personal Digital Assistant, Google Glass, Samsung
Smartwatch etc.)

2. On a scale from 1 to 6 (with 1=never, 2=rarely, 3=sometimes, 4=often, 5=all the time, and
6=do not own), how often do you use the following ?
Note: If yo do not own one of the following devices, select ‘Do not own’; if you own the
device but do not use it, select ‘Never’.
1
Never

2
Rarely

3
Sometimes

Landline
Cell phone
Smartphone
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4
Often

5
All the time

6
Do not own

Tablet
Laptop
PC
Other
II.

Cell Phone/Smartphone Use

1. How many cell phones (including Smartphones) have you ever owned?
2. How many cell phones (including Smartphones) do you own currently?
3. Given below are different types of activities that cell phones can be used for. On a scale
from 1 to 5 (with 1=never, 2=rarely, 3=sometimes, 4=often, 5=all the time), please indicate
how often you engage in the following activities on your cell phone or Smartphone.
Note: If your cell phone does not have a particular feature allowing you to carry out one or
more of the following activities, select ‘N/A’; however, if your cell phone has the feature but
you do no use it for that activity, then select ‘Never’. For example, if your cell phone does
not have internet capability, select N/A for internet-related activities like accessing the
internet, sending or receiving emails, online banking etc. However, if your cell phone has
internet capability and you do not use it, then select ‘Never’.
Never

Rarely

Sometimes

Often

All the time

N/A

Make or receive phone calls
Take a picture
Record video
Send or receive text
messages
Access the internet
Send or receive emails
Download applications
Listen to music
Watch videos
Online banking
Play games
Online social networking
(e.g., Facebook, Twitter,
etc.)
Use health-related apps
Reading e-books
III.

mHealth Acceptance

Mobile technologies such as cell phones can be used in several ways to influence health
outcomes, such as assessing health markers, reminding patients about medication intake and
tracking health behaviors. This use of mobile technology in health research is called mHealth.
1. On a scale from 1 to 5 (with 1 being ‘not interested at all’ and 5 being ‘extremely interested’),
how interested would you be in using mHealth to remind you to take your medication?
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1
Not interested
at all

2
Slightly
interested

3
Somewhat
interested

4
Moderately
interested

5
Extremely
interested

IF ‘NOT INTERESTED AT ALL’, SKIP TO QUESTION 4.
2. How frequently are you interested to receive reminders (via phone calls, text messaes,
and/or emails) to remind you to take your medication?
Daily

Weekly

Monthly

3. Which of the following would you prefer the most to receive a reminder to take your
medication? (choose one)
Phone call

Text messages

Emails

They are all equally fine

4. On a scale from 1 to 5 (with 1 being ‘not interested at all’ and 5 being ‘extremely interested’),
how interested would you be in using mHealth devices to receive information about HIV?
1
Not interested
at all

2

3
Somewhat
interested

4

5
Extremely
interested

IF ‘NOT INTERESTED AT ALL’, SKIP TO QUESTION 7.
5. How frequently are you interested to receive information about HIV using mHealth devices
(via phone calls, text messaes, and/or emails)?
Daily

Weekly

Monthly

6. Which of the following would you prefer the most to receive information about HIV (choose
one):
Phone call

Text messages

Emails

They are all equally fine

7. On a scale from 1 to 5 (with 1 being ‘not interested at all’ and 5 being ‘extremely interested’),
how interested would you be in using mHealth in assessing your health behaviors?
1
Not interested
at all

2

3
Somewhat
interested

4

5
Extremely
interested

IF ‘NOT INTERESTED AT ALL’, SKIP TO SECTION V.
8. On a scale from 1 to 5 (with 1 being ‘not interested at all’ and 5 being ‘extremely interested’),
how interested would you be in using mHealth in assessing drug use behaviors?
1
Not interested
at all

2

3
Somewhat
interested
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4

5
Extremely
interested

9. On a scale from 1 to 5 (with 1 being ‘not interested at all’ and 5 being ‘extremely interested’),
how interested would you be in using mHealth in assessing your sexual behaviors?
1
Not interested
at all

2

3
Somewhat
interested

4

5
Extremely
interested

Brief Inventory of Neurocognitive Impairment (BINI) Scale
Below is a list of problems which some people have. Please read each one carefully, and ask
yourself how much that statement applies to you, in the past month.
Statements

0
Not at all

1
Slightly

I have trouble concentrating.
My mind won't stay on any one
thing.
I have difficulty paying attention.
My mind tends to wander.
I often feel restless.
I am easily distracted.
I have trouble making up my mind.
I have difficulty making decisions.
I forget what I read.
I feel frustrated quite often.
My judgment is poor.
Something is wrong with my mind.’
I have trouble remembering
important things.
My thinking becomes blocked.
I fall apart under pressure.
I tend to give up easily.
I forget where I put things.
I feel everything is an effort.
I often lose things.
I get lost easily.
My mind frequently goes blank.
My reactions are slow.
My arithmetic is poor.
Doing simple math problems in my
head is difficult.
I count with my fingers.
I do things slowly.
My mind is dull.
I forget the names of common
things.
I have trouble learning new things.
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2
Somewhat

3
Moderately

4
Extremely

I have forgotten much what learned
in school.
My words get mixed up.
I have trouble writing sentences.
My mind works slowly.
My hearing has become worse.
I have trouble following
conversations.
I have serious memory problems.
I am forgetful.
I have trouble remembering
people’s names.
I have forgotten many things from
my childhood.
I am very clumsy.
I drop things frequently.
I bump into things.
I fall down sometimes.
I faint sometimes.
I have trouble with the left side of
my body.
Part of my body is paralyzed.
Part of my body feels numb.
I have trouble walking.
I have trouble with the right side of
my body.
I have a bad temper.
I have urges to break and smash
things.
I get into arguments frequently.
I have trouble sleeping.
I suffer from severe pain.
I have severe headaches.
I have had a head injury.
I have been knocked unconscious.
Pre-Exposure Prophylaxis (PrEP)
There is a new way to prevent HIV infection for people who may be exposed to the virus. It is
called Pre-Exposure Prophylaxis or PrEP. The use of anti-HIV medication can keep HIV
negative people from becoming infected. When taken properly, PrEP is safe and highly effective
(up to 99%) in preventing HIV infection. The key is taking one pill every day.
1. Before participating in this survey, have you ever heard about PrEP?
0
1
No
Yes
2. Where did you hear about PrEP? Check all that apply.
a. A friend
b. A family member
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c.
d.
e.
f.
g.
h.
i.

A healthcare provider
A work colleague
An HIV prevention counselor
On a website
At a community meeting
From a newspaper
Other

3. Have you ever used PrEP?
0
1
No
Yes
IMB Items for PrEP
Information
1. Uninfected individuals who are at high risk of HIV infection (e.g., through unsafe sex or
needle sharing) should take PrEP.
0
1
False
True
2. PrEP is highly effective for preventing HIV if it is taken on a daily basis.
0
1
False
True
3. Before taking PrEP, people need to be tested to confirm that they are not already
infected with HIV.
0
1
False
True
4. When on PrEP, I don’t need to use new or clean needles.
0
1
False
True
5. PrEP provides protection against other sexually transmitted infections (STIs), like
gonorrhea and chlamydia.
0
1
False
True
6. When on PrEP, I don’t need to use condoms.
0
1
False
True
7. I can stop taking PrEP if my risk of getting HIV infection becomes low because of
changes in my life.
0
1
False
True
8. While I’m on PrEP, I will need to go for regular doctor visits.
0
1
False
True
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9. The cost associated with the PrEP medication is not covered by the insurance.
0
1
2
3
4
Strongly
Disagree
Neither agree
Agree
Strongly
disagree
or disagree
agree
10. PrEP does not provide complete protection against HIV.
0
1
2
3
Strongly
Disagree
Neither agree
Agree
disagree
or disagree

4
Strongly
agree

11. Taking PrEP means I am putting myself at risk for HIV.
0
1
2
3
Strongly
Disagree
Neither agree
Agree
disagree
or disagree

4
Strongly
agree

12. The short-term side-effects of PrEP may include nausea and dizziness.
0
1
False
True
Motivation
1. It is important to me to not to get sexually transmitted infections (STIs), including HIV, in
the next year.
0
1
2
3
4
Not important
Slightly
Neutral
Very
Extremely
at all
important
important
important
2. How satisfied are you with your current method of HIV protection (e.g., condom use,
clean needle use)?
0
1
2
3
4
Very
Dissatisfied
Unsure
Satisfied
Very
dissatisfied
satisfied
3. If I were on PrEP, I’m sure that PrEP would be effective in protecting me from HIVinfection
0
1
2
3
4
Strongly
Disagree
Neither agree
Agree
Strongly
disagree
or disagree
agree
4. I think I would be less worried about HIV infection if I were on PrEP.
0
1
2
3
4
Strongly
Disagree
Neither agree
Agree
Strongly
disagree
or disagree
agree
5. If I were on PrEP, it would take the worry out of the sex.
0
1
2
3
Strongly
Disagree
Neither agree
Agree
disagree
or disagree

4
Strongly
agree

6. If I were on PrEP, I would NOT be concerned about the potential side-effects of PrEP.
0
1
2
3
4
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Strongly
disagree

Disagree

Neither agree
or disagree

Agree

Strongly
agree

7. I feel uncomfortable being prescribed a new medication.
0
1
2
3
Strongly
Disagree
Neither agree
Agree
disagree
or disagree

4
Strongly
agree

8. If I were on PrEP, taking it properly as prescribed would be hard.
0
1
2
3
Strongly
Disagree
Neither agree
Agree
disagree
or disagree

4
Strongly
agree

9. If I were on PrEP, I won’t have to worry about using condoms.
0
1
2
3
Strongly
Disagree
Neither agree
Agree
disagree
or disagree

4
Strongly
agree

10. If I were on PrEP, I won’t have to worry about sharing needles and works.
0
1
2
3
4
Strongly
Disagree
Neither agree
Agree
Strongly
disagree
or disagree
agree
11. If I were on PrEP, I won’t have to worry about my partner’s HIV status.
0
1
2
3
4
Strongly
Disagree
Neither agree
Agree
Strongly
disagree
or disagree
agree
12. I’m not concerned about the cost associated with PrEP medication.
0
1
2
3
4
Strongly
Disagree
Neither agree
Agree
Strongly
disagree
or disagree
agree
13. I would take PrEP if I know someone (e.g., friend, family member) who is currently taking
it.
0
1
2
3
4
Strongly
Disagree
Neither agree
Agree
Strongly
disagree
or disagree
agree
14. I have a responsibility to contribute to HIV prevention efforts by using PrEP.
0
1
2
3
4
Strongly
Disagree
Neither agree
Agree
Strongly
disagree
or disagree
agree
15. I have family members or friends to encourage me to take PrEP properly.
0
1
2
3
4
Strongly
Disagree
Neither agree
Agree
Strongly
disagree
or disagree
agree
16. If I disclose that I’m on PrEP to my sex partner, he/she will be comfortable with it.
0
1
2
3
4
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Strongly
disagree

Disagree

Neither agree
or disagree

Agree

Strongly
agree

Behavioral Skills
Questions

0
1
2
3
4
Not at all Somewhat Moderately
Very
Completely
confident confident
confident confident confident

How confident are you that you would
remember to take PrEP every day?
How confident are you that you would
stick to your PrEP regimen even if
you have some side-effects (e.g.,
nausea)?
How confident are you that you could
make PrEP part of your daily routine?
How confident are you that you could
get PrEP refills before you run out?
How confident are you that you could
fill your PrEP prescription no matter
what it costs?
How confident are you that you could
continue with your PrEP regimen
even if getting to your clinic
appointments is a major hassle?
How confident are you that you would
use condoms while on PrEP?
How confident are you that you would
stop sharing needles or works while
on PrEP?
How confident are you that you could
continue with your PrEP regimen
even when people close to you say it
isn’t a good idea.
How confident are you that you could
discuss using PrEP with your partner.
How confident are you that you could
use PrEP even if your partner didn’t
like it.
Intent to use PrEP
1. I would be interested in taking PrEP to reduce my current risk of HIV infection.
0
1
No
Yes
Drug use
The next section will contain some questions about your use of drugs.
1. Have you used any illicit drugs in the pasts 3 months?
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a. Yes
b. No
2. In the last 3 months, which illicit drug have you used?
a. Heroin
b. Cocaine
c. OxyContin
d. Crystal meth
e. Percocet
f. Marijuana
g. others
3. In the last 3 months, what has been your primary method of illicit opiate use?
a. IV injection
b. Smoke
c. Snort
d. Oral
e. Non-IV injection
4. In the last 3 months, have you injected any illicit drugs?
a. Yes
b. No
The HIV Risk-Taking Behavior Scale (HRBS)
Now, I'm going to ask you a few questions about your drug use for the last month, and, The next
part of the questionnaire concerns your sex life over the last month.
Questions
How many times have you hit up (i.e.
injected any drugs) in the last month?

0
Hasn’t
hit up

How many times in the last month
have you used a needle after
someone else had already used it?
How many different people have used
a needle before you in the last
month?
How many times in the last month
has someone used a needle after you
have used it?
How often, in the last month, have
you cleaned needles before re-using
them?
Before using needles again, how
often in the last month did you use
bleach to clean them?

No
times

1
Once
a
week
or less
One
time

None

One
Two people
person

3-5
people

6-10
people

None

One
Two people
person

3-5
people

6-10
people

Doesn’t
re-use

Every
time

Often

Sometim
es

Rarely

5
More
thaan 3
times a
day
More
than 10
times
More
than 10
people
More
than 10
people
Never

Doesn’t
re-use

Every
time

Often

Sometim
es

Rarely

Never
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2
More than
once a week
(but less than
once a day)
Two times

3
Once a
day

4
2-3
times a
day

3-5 times

6-10
times

How many people, including clients,
have you had sex with in the last
month?
How often have you used condoms
when having sex with your regular
partner(s) in the last month?
How often did you use condoms
when you had sex with casual
partners?
How often have you used condoms
when you have been paid for sex in
the last month?
How many times did you have anal
sex in the last month?

None

One
Two people
person

3-5
people

6-10
people

No
regular
partner
No
casual
partners
No paid
sex

Every
time

Often

Sometim
es

Rarely

More
than 10
people
Never

Every
time

Often

Sometim
es

Rarely

Never

Every
time

Often

Sometie
ms

Rarely

Never

No
times

One
time

Two times

3-5 times

6-10
times

More
than 10
times

1. What do you think your current risk of getting HIV is? Please consider your involvement in
HIV transmission risk behaviors (e.g., needle sharing, no condom use) if applicable.
a. No risk at all
b. A little bit of risk
c. More than a little bit of risk
d. A lot of risk
2. Have you ever been diagnosed with any sexually transmitted infections (other than HIV)
in the last 12 months? For example: Chlamydia, gonorrhea, syphilis, herpes, genital
warts, etc.
a. Yes
b. No
Medication Adherence
1. In the last 30 days, haave you taken any medications?
a. Yes
b. No
2. In the last 30 days, on how many days did you miss at least one dose of any of the
medication you are taking?
3. In the last 30 days, how often did you take your medication in the way you were
supposed to?
1. Never
2. Rarely
3. Sometimes
4. Usually
5. Almost always
6. Excellent
4. In the last 30 days, how good a job did you do at taking your medication in the way you
were supposed to?
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1.
2.
3.
4.
5.
6.

Very poor
Poor
Fair
Good
Very good
excellent
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